# IPASS (NCT00322452)

> First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00322452
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: AstraZeneca
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Gefitinib; Carboplatin; Paclitaxel
- Enrollment: 1329
- Primary outcome: Median Progression Free Survival (PFS) in Months

## Commentary we found

- X threads: 16
- Podcasts: 12
- YouTube: 8

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=ipass-nct00322452

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT00322452", "email": "<work email>"}; the inbox owner confirms by the emailed link.